In vivo, AZD5363 inhibits tumor growth in xenograft tumor models and maintains pharmacodynamic activity for at least 24 hours.215 Preclinical sensitivity to AZD5363 is strongly associated with the presence of PIK3CA, and this trend has also been observed for other inhibitors of the PI3K/Akt/mTOR pathway.216. This evidence concerns the gene AKT1 and neoplasm.